Benign Prostatic Hyperplasia (BPH): IPSS Score, PSA Testing, and Urinary Management
Background: Benign prostatic hyperplasia refers to a benign adenomatous proliferation of the transition zone within the prostate. This affects >70% of men over the age of 60 years. Describe the presentation of obstructive / irritative lower urinary tract symptoms. Describe the scoring system (IPSS), assessment of PSA levels, management with alpha-1 blockers, 5-alpha reductase inhibitors and minimally invasive surgical interventions.
Hands-free audio narration
This educational guide is researched in accordance with our Editorial Policy and public health guidelines. It is not personal medical advice. For clinical questions, read our Medical Disclaimer or consult a qualified healthcare provider.
Quick Summary & Key Findings
Benign prostatic hyperplasia is caused by the prostate gland growing due to DHT. This causes pressure on the prostatic urethra. Common symptoms include increased frequency of urinating at night, a slow urine stream, difficulty starting urination and post void dribbling. Diagnosis can be made using a digital rectal examination (DRE), blood tests to measure the PSA levels and the international prostate symptom score. Medical management includes alpha-1 antagonists (tamsulosin) which cause fast relaxation of muscles. 5-alpha reductase inhibitors (finasteride) can also be used to reduce prostate size.
The prostate gland is a walnut sized gland in males, located below the urinary bladder surrounding the proximal end of the urethra. At around the age of 40, increased cell growth in the central transition zone causes gradual enlargement of the prostate gland due to long term exposure to DHT.
This causes benign prostatic hyperplasia (BPH), an extremely common age related condition. Over 50% of men in their 50s are affected by BPH and up to 80% of men in their 70s. The enlarged prostate tissue causes obstruction of the urethra causing the detrusor muscle of the bladder to increase pressure.
If left untreated BPH can cause issues such as detrusor hypertrophy, frequent UTIs, urinary retention, bladder stones and secondary hydronephrosis. Knowing the difference between benign growth and cancerous growth will help men get the right investigations and treatment available today which will improve quality of life and preserve bladder function.
Symptom Classification and the IPSS Diagnostic Questionnaire
Pharmacological Treatments: Alpha-Blockers vs. 5-ARIs
Minimally Invasive and Surgical Therapies
Urodynamic Progression, Transition Zone Hyperplasia & The Landmark MTOPS Trial
Minimally Invasive Surgical Therapies (MIST) vs Standard Resection Modalities
IPSS Symptom Score Stratification, Uroflowmetry Curves & PVR Retention Triage
Clinical Comparison: Pharmacological & Minimally Invasive BPH Modalities
| Therapeutic Modality | Primary Mechanism | Onset of Symptom Relief | Impact on Prostate Volume | Ejaculatory / Sexual Profile |
|---|---|---|---|---|
| Alpha-1A Adrenergic Antagonists (Tamsulosin 0.4mg, Silodosin 8mg) | Relaxes smooth muscle tone in the prostatic stroma, bladder neck, and prostatic urethra | Rapid relief within 3 to 7 days | No reduction in prostate volume; does not alter PSA or halt long-term tissue growth | Risk of retrograde ejaculation (up to 28% with silodosin) and intraoperative floppy iris syndrome (IFIS) during cataract surgery. |
| 5-Alpha-Reductase Inhibitors (Finasteride 5mg, Dutasteride 0.5mg) | Inhibits 5-AR isoenzymes, blocking conversion of testosterone to dihydrotestosterone (DHT) | Delayed relief requiring 3 to 6 months of daily therapy | Reduces prostate volume by 20–25% and reduces 4-year acute urinary retention risk by 57% | Reduces serum PSA by 50% (multiply measured PSA by 2 for accurate cancer screening); 3–5% risk of erectile dysfunction and decreased libido. |
| Phosphodiesterase-5 Inhibitor (Tadalafil 5mg daily) | Increases intracellular cyclic GMP, relaxing detrusor and prostatic smooth muscle | 1 to 2 weeks | Zero reduction in prostate size; does not alter urinary retention progression | Improves concurrent erectile dysfunction; strictly contraindicated with concurrent nitrate medications due to severe systemic hypotension. |
| Water Vapor Thermal Therapy (Rezūm System) | Transurethral delivery of radiofrequency water vapor inducing targeted cellular necrosis in transition zone | Gradual improvement over 4 to 12 weeks | Ablates obstructive adenoma tissue and median lobe | Minimally invasive outpatient procedure under local anesthesia; preserves erectile and ejaculatory function in over 90% of men. |
| Holmium Laser Enucleation (HoLEP) | Complete anatomical enucleation of entire prostate adenoma along the surgical capsule | Immediate relief within 24–48 hours post-catheter removal | Removes up to 80–90% of transition zone tissue (effective for prostates >100 cm3) | Lowest long-term re-operation rate (<1% at 10 years); high incidence of retrograde ejaculation (>75%), but preserves erectile nerve function. |
Frequently Asked Questions
Dr. Naresh Trehan, MBBS, MD, FACS
Chairman & Chief Cardiac Surgeon, Medanta – The Medicity • MBBS, MD (Cardiothoracic Surgery), FACSDr. Naresh Trehan is a world-renowned cardiovascular and cardiothoracic surgeon, Founder, and Chairman of Medanta – The Medicity, Gurugram. With over 40 years of pioneering surgical experience, he has performed more than 48,000 successful open-heart surgeries and leads cardiovascular clinical literacy at mediguide4u.
References & Clinical Resources
- Clinical Research Faculty & Editorial Team. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2020-2026). [Access Resource Link] — Journal of Urology / American Urological Association
- Clinical Research Faculty & Editorial Team. EAU Guidelines on the Management of Non-neurogenic Male LUTS, incl. Benign Prostatic Obstruction (2020-2026). [Access Resource Link] — European Association of Urology
- Clinical Research Faculty & Editorial Team. The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia (MTOPS Study) (2020-2026). [Access Resource Link] — New England Journal of Medicine
Related Healthcare Guides
Active Aging: Complete Mobility, Sarcopenia Prevention, and Bone Health Guide for Seniors
Chronic Kidney Disease (CKD): Stages, eGFR Decline, Potassium, and Renal Nutrition
Osteoporosis and Bone Mineral Density: DEXA Scans, Calcium, and Fall Prevention
Reader Reviews & Clinical Q&A
Real experiences, reader questions, and verified physician guidance.
At 72, I was concerned about muscle loss and fatigue. Implementing the protein distribution and resistance training suggestions here has significantly improved my balance and energy levels.
That is wonderful to hear, Gerald! Preserving lean muscle mass and motor unit recruitment through progressive resistance training is the foundation of healthy longevity.
The inclusion of the AGS Beers Criteria and anticholinergic risk scores makes this an invaluable educational asset for patients and families navigating polypharmacy.
Deprescribing and medication reconciliation are critical safety imperatives in geriatric care, Dr. Steven. Thank you for championing patient safety.